Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics
Multidrug-resistant bacterial infections are a global health threat. Nanoparticles are thus investigated as novel antibacterial agents for clinical practice, including wound dressings and implants. We report that nanoparticles' bactericidal activity strongly depends on their physical binding to...
Gespeichert in:
Veröffentlicht in: | Biomaterials 2019-02, Vol.192, p.551-559 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 559 |
---|---|
container_issue | |
container_start_page | 551 |
container_title | Biomaterials |
container_volume | 192 |
creator | Siemer, Svenja Westmeier, Dana Barz, Matthias Eckrich, Jonas Wünsch, Désirée Seckert, Christof Thyssen, Christian Schilling, Oliver Hasenberg, Mike Pang, Chengfang Docter, Dominic Knauer, Shirley K. Stauber, Roland H. Strieth, Sebastian |
description | Multidrug-resistant bacterial infections are a global health threat. Nanoparticles are thus investigated as novel antibacterial agents for clinical practice, including wound dressings and implants. We report that nanoparticles' bactericidal activity strongly depends on their physical binding to pathogens, including multidrug-resistant primary clinical isolates, such as Staphylococcus aureus, Klebsiella pneumoniae or Enterococcus faecalis. Using controllable nanoparticle models, we found that nanoparticle-pathogen complex formation was enhanced by small nanoparticle size rather than material or charge, and was prevented by 'stealth' modifications. Nanoparticles seem to preferentially bind to Gram-positive pathogens, such as Listeria monocytogenes, S. aureus or Streptococcus pyrogenes, correlating with enhanced antibacterial activity. Bacterial resistance to metal-based nanoparticles was mediated by biomolecule coronas acquired in pathophysiological environments, such as wounds, the lung, or the blood system. Biomolecule corona formation reduced nanoparticles' binding to pathogens, but did not impact nanoparticle dissolution. Our results provide a mechanistic explanation why nano-sized antibiotics may show reduced activity in clinically relevant environments, and may inspire future nanoantibiotic designs with improved and potentially pathogen-specific activity. |
doi_str_mv | 10.1016/j.biomaterials.2018.11.028 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2155167521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0142961218308111</els_id><sourcerecordid>2155167521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-828d259fe9b024f046ad25218964e15c14df7c8612e430a441025799aba3af473</originalsourceid><addsrcrecordid>eNqNkc1u1TAQhS0EopfCKyCLFZsE23ESpzsof5UqdVPWluOMiy-JfbGdSrxHH5hJb0FddmWNdM43PnMIecdZzRnvPuzr0cfFFEjezLkWjKua85oJ9YzsuOpV1Q6sfU52jEtRDR0XJ-RVznuGM5PiJTlpWNswIeWO3H1CVJzBrjNUNqYYDHUxId3HQG0MDlKmCbLPxQQLNDo6Gnu_m5ZIgwnxYFLxFv0-TKuFif7y8-zDzRm9WA6zt_esvGFp-Ql0QthN2EB-OaR4i4aNYkLxmAtJ-TV54TAZvHl4T8mPr1-uz79Xl1ffLs4_Xla2UaxUSqhJtIODYcQwjsnO4Cy4GjoJvLVcTq63CvODbJiRkjPR9sNgRtMYJ_vmlLw_cvEbv1fIRS8-W5hnEyCuWQvetrzrEYnSs6PUpphzAqcPyS8m_dGc6a0VvdePW9FbK5pzja2g-e3DnnVcYPpv_VcDCj4fBYBpbz0kna0HPPfkE9iip-ifsucv7j-odg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2155167521</pqid></control><display><type>article</type><title>Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Siemer, Svenja ; Westmeier, Dana ; Barz, Matthias ; Eckrich, Jonas ; Wünsch, Désirée ; Seckert, Christof ; Thyssen, Christian ; Schilling, Oliver ; Hasenberg, Mike ; Pang, Chengfang ; Docter, Dominic ; Knauer, Shirley K. ; Stauber, Roland H. ; Strieth, Sebastian</creator><creatorcontrib>Siemer, Svenja ; Westmeier, Dana ; Barz, Matthias ; Eckrich, Jonas ; Wünsch, Désirée ; Seckert, Christof ; Thyssen, Christian ; Schilling, Oliver ; Hasenberg, Mike ; Pang, Chengfang ; Docter, Dominic ; Knauer, Shirley K. ; Stauber, Roland H. ; Strieth, Sebastian</creatorcontrib><description>Multidrug-resistant bacterial infections are a global health threat. Nanoparticles are thus investigated as novel antibacterial agents for clinical practice, including wound dressings and implants. We report that nanoparticles' bactericidal activity strongly depends on their physical binding to pathogens, including multidrug-resistant primary clinical isolates, such as Staphylococcus aureus, Klebsiella pneumoniae or Enterococcus faecalis. Using controllable nanoparticle models, we found that nanoparticle-pathogen complex formation was enhanced by small nanoparticle size rather than material or charge, and was prevented by 'stealth' modifications. Nanoparticles seem to preferentially bind to Gram-positive pathogens, such as Listeria monocytogenes, S. aureus or Streptococcus pyrogenes, correlating with enhanced antibacterial activity. Bacterial resistance to metal-based nanoparticles was mediated by biomolecule coronas acquired in pathophysiological environments, such as wounds, the lung, or the blood system. Biomolecule corona formation reduced nanoparticles' binding to pathogens, but did not impact nanoparticle dissolution. Our results provide a mechanistic explanation why nano-sized antibiotics may show reduced activity in clinically relevant environments, and may inspire future nanoantibiotic designs with improved and potentially pathogen-specific activity.</description><identifier>ISSN: 0142-9612</identifier><identifier>EISSN: 1878-5905</identifier><identifier>DOI: 10.1016/j.biomaterials.2018.11.028</identifier><identifier>PMID: 30530244</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adsorption ; Anti-Bacterial Agents - pharmacology ; Antibiotic nanomaterials ; Bacteria ; Biocorona ; Drug Resistance, Multiple, Bacterial - drug effects ; Escherichia coli - drug effects ; Escherichia coli - ultrastructure ; Implants ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; MRSA ; Multidrug-resistant pathogens ; Nanomedicine ; Nanoparticles ; Nanoparticles - chemistry ; Nanoparticles - ultrastructure ; Resistance</subject><ispartof>Biomaterials, 2019-02, Vol.192, p.551-559</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-828d259fe9b024f046ad25218964e15c14df7c8612e430a441025799aba3af473</citedby><cites>FETCH-LOGICAL-c380t-828d259fe9b024f046ad25218964e15c14df7c8612e430a441025799aba3af473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biomaterials.2018.11.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30530244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siemer, Svenja</creatorcontrib><creatorcontrib>Westmeier, Dana</creatorcontrib><creatorcontrib>Barz, Matthias</creatorcontrib><creatorcontrib>Eckrich, Jonas</creatorcontrib><creatorcontrib>Wünsch, Désirée</creatorcontrib><creatorcontrib>Seckert, Christof</creatorcontrib><creatorcontrib>Thyssen, Christian</creatorcontrib><creatorcontrib>Schilling, Oliver</creatorcontrib><creatorcontrib>Hasenberg, Mike</creatorcontrib><creatorcontrib>Pang, Chengfang</creatorcontrib><creatorcontrib>Docter, Dominic</creatorcontrib><creatorcontrib>Knauer, Shirley K.</creatorcontrib><creatorcontrib>Stauber, Roland H.</creatorcontrib><creatorcontrib>Strieth, Sebastian</creatorcontrib><title>Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics</title><title>Biomaterials</title><addtitle>Biomaterials</addtitle><description>Multidrug-resistant bacterial infections are a global health threat. Nanoparticles are thus investigated as novel antibacterial agents for clinical practice, including wound dressings and implants. We report that nanoparticles' bactericidal activity strongly depends on their physical binding to pathogens, including multidrug-resistant primary clinical isolates, such as Staphylococcus aureus, Klebsiella pneumoniae or Enterococcus faecalis. Using controllable nanoparticle models, we found that nanoparticle-pathogen complex formation was enhanced by small nanoparticle size rather than material or charge, and was prevented by 'stealth' modifications. Nanoparticles seem to preferentially bind to Gram-positive pathogens, such as Listeria monocytogenes, S. aureus or Streptococcus pyrogenes, correlating with enhanced antibacterial activity. Bacterial resistance to metal-based nanoparticles was mediated by biomolecule coronas acquired in pathophysiological environments, such as wounds, the lung, or the blood system. Biomolecule corona formation reduced nanoparticles' binding to pathogens, but did not impact nanoparticle dissolution. Our results provide a mechanistic explanation why nano-sized antibiotics may show reduced activity in clinically relevant environments, and may inspire future nanoantibiotic designs with improved and potentially pathogen-specific activity.</description><subject>Adsorption</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotic nanomaterials</subject><subject>Bacteria</subject><subject>Biocorona</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - ultrastructure</subject><subject>Implants</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>MRSA</subject><subject>Multidrug-resistant pathogens</subject><subject>Nanomedicine</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Nanoparticles - ultrastructure</subject><subject>Resistance</subject><issn>0142-9612</issn><issn>1878-5905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1TAQhS0EopfCKyCLFZsE23ESpzsof5UqdVPWluOMiy-JfbGdSrxHH5hJb0FddmWNdM43PnMIecdZzRnvPuzr0cfFFEjezLkWjKua85oJ9YzsuOpV1Q6sfU52jEtRDR0XJ-RVznuGM5PiJTlpWNswIeWO3H1CVJzBrjNUNqYYDHUxId3HQG0MDlKmCbLPxQQLNDo6Gnu_m5ZIgwnxYFLxFv0-TKuFif7y8-zDzRm9WA6zt_esvGFp-Ql0QthN2EB-OaR4i4aNYkLxmAtJ-TV54TAZvHl4T8mPr1-uz79Xl1ffLs4_Xla2UaxUSqhJtIODYcQwjsnO4Cy4GjoJvLVcTq63CvODbJiRkjPR9sNgRtMYJ_vmlLw_cvEbv1fIRS8-W5hnEyCuWQvetrzrEYnSs6PUpphzAqcPyS8m_dGc6a0VvdePW9FbK5pzja2g-e3DnnVcYPpv_VcDCj4fBYBpbz0kna0HPPfkE9iip-ifsucv7j-odg</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Siemer, Svenja</creator><creator>Westmeier, Dana</creator><creator>Barz, Matthias</creator><creator>Eckrich, Jonas</creator><creator>Wünsch, Désirée</creator><creator>Seckert, Christof</creator><creator>Thyssen, Christian</creator><creator>Schilling, Oliver</creator><creator>Hasenberg, Mike</creator><creator>Pang, Chengfang</creator><creator>Docter, Dominic</creator><creator>Knauer, Shirley K.</creator><creator>Stauber, Roland H.</creator><creator>Strieth, Sebastian</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201902</creationdate><title>Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics</title><author>Siemer, Svenja ; Westmeier, Dana ; Barz, Matthias ; Eckrich, Jonas ; Wünsch, Désirée ; Seckert, Christof ; Thyssen, Christian ; Schilling, Oliver ; Hasenberg, Mike ; Pang, Chengfang ; Docter, Dominic ; Knauer, Shirley K. ; Stauber, Roland H. ; Strieth, Sebastian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-828d259fe9b024f046ad25218964e15c14df7c8612e430a441025799aba3af473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adsorption</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotic nanomaterials</topic><topic>Bacteria</topic><topic>Biocorona</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - ultrastructure</topic><topic>Implants</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>MRSA</topic><topic>Multidrug-resistant pathogens</topic><topic>Nanomedicine</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Nanoparticles - ultrastructure</topic><topic>Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siemer, Svenja</creatorcontrib><creatorcontrib>Westmeier, Dana</creatorcontrib><creatorcontrib>Barz, Matthias</creatorcontrib><creatorcontrib>Eckrich, Jonas</creatorcontrib><creatorcontrib>Wünsch, Désirée</creatorcontrib><creatorcontrib>Seckert, Christof</creatorcontrib><creatorcontrib>Thyssen, Christian</creatorcontrib><creatorcontrib>Schilling, Oliver</creatorcontrib><creatorcontrib>Hasenberg, Mike</creatorcontrib><creatorcontrib>Pang, Chengfang</creatorcontrib><creatorcontrib>Docter, Dominic</creatorcontrib><creatorcontrib>Knauer, Shirley K.</creatorcontrib><creatorcontrib>Stauber, Roland H.</creatorcontrib><creatorcontrib>Strieth, Sebastian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomaterials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siemer, Svenja</au><au>Westmeier, Dana</au><au>Barz, Matthias</au><au>Eckrich, Jonas</au><au>Wünsch, Désirée</au><au>Seckert, Christof</au><au>Thyssen, Christian</au><au>Schilling, Oliver</au><au>Hasenberg, Mike</au><au>Pang, Chengfang</au><au>Docter, Dominic</au><au>Knauer, Shirley K.</au><au>Stauber, Roland H.</au><au>Strieth, Sebastian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics</atitle><jtitle>Biomaterials</jtitle><addtitle>Biomaterials</addtitle><date>2019-02</date><risdate>2019</risdate><volume>192</volume><spage>551</spage><epage>559</epage><pages>551-559</pages><issn>0142-9612</issn><eissn>1878-5905</eissn><abstract>Multidrug-resistant bacterial infections are a global health threat. Nanoparticles are thus investigated as novel antibacterial agents for clinical practice, including wound dressings and implants. We report that nanoparticles' bactericidal activity strongly depends on their physical binding to pathogens, including multidrug-resistant primary clinical isolates, such as Staphylococcus aureus, Klebsiella pneumoniae or Enterococcus faecalis. Using controllable nanoparticle models, we found that nanoparticle-pathogen complex formation was enhanced by small nanoparticle size rather than material or charge, and was prevented by 'stealth' modifications. Nanoparticles seem to preferentially bind to Gram-positive pathogens, such as Listeria monocytogenes, S. aureus or Streptococcus pyrogenes, correlating with enhanced antibacterial activity. Bacterial resistance to metal-based nanoparticles was mediated by biomolecule coronas acquired in pathophysiological environments, such as wounds, the lung, or the blood system. Biomolecule corona formation reduced nanoparticles' binding to pathogens, but did not impact nanoparticle dissolution. Our results provide a mechanistic explanation why nano-sized antibiotics may show reduced activity in clinically relevant environments, and may inspire future nanoantibiotic designs with improved and potentially pathogen-specific activity.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30530244</pmid><doi>10.1016/j.biomaterials.2018.11.028</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0142-9612 |
ispartof | Biomaterials, 2019-02, Vol.192, p.551-559 |
issn | 0142-9612 1878-5905 |
language | eng |
recordid | cdi_proquest_miscellaneous_2155167521 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adsorption Anti-Bacterial Agents - pharmacology Antibiotic nanomaterials Bacteria Biocorona Drug Resistance, Multiple, Bacterial - drug effects Escherichia coli - drug effects Escherichia coli - ultrastructure Implants Microbial Sensitivity Tests Microbial Viability - drug effects MRSA Multidrug-resistant pathogens Nanomedicine Nanoparticles Nanoparticles - chemistry Nanoparticles - ultrastructure Resistance |
title | Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T21%3A39%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomolecule-corona%20formation%20confers%20resistance%20of%20bacteria%20to%20nanoparticle-induced%20killing:%20Implications%20for%20the%20design%20of%20improved%20nanoantibiotics&rft.jtitle=Biomaterials&rft.au=Siemer,%20Svenja&rft.date=2019-02&rft.volume=192&rft.spage=551&rft.epage=559&rft.pages=551-559&rft.issn=0142-9612&rft.eissn=1878-5905&rft_id=info:doi/10.1016/j.biomaterials.2018.11.028&rft_dat=%3Cproquest_cross%3E2155167521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2155167521&rft_id=info:pmid/30530244&rft_els_id=S0142961218308111&rfr_iscdi=true |